Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy and safety of Qishen Yiqi drop pill for coronary heart disease: An overview of systematic review and meta-analysis

Jingwen Yan¹, Chaorong Zhang², Xiaohui Chen², Jiaqi Yan², Wanwen Zhu³, Lili Jin^4-6 Weiqing Yu^4-6

¹Panyu Hospital of Chinese Medicine,Guangzhou, Guangdong,511408, China; ²Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China; ³Guangzhou Baiyun District Jianggao Town Health Centre, Guangzhou, Guangdong Province 510450, China; ⁴Guangdong Provincial Second Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong Province 510095, China; ⁵Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine, Guangzhou, Guangdong Province 510095, China; ⁶The Fifth Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510095, China.

For correspondence:- Lili Jin Email: jinlili991@163.com

Accepted: 19 May 2024 Published: 30 June 2024

Citation: Yan J, Zhang C, Chen X, Yan J, Zhu W, Jin L, et al. Efficacy and safety of Qishen Yiqi drop pill for coronary heart disease: An overview of systematic review and meta-analysis. Trop J Pharm Res 2024; 23(6):1009-1020 doi: 10.4314/tjpr.v23i6.12

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate current pieces of evidence on Qishen Yiqi drop pill (QSYQ) in coronary heart disease (CHD).

Methods: All systematic reviews (SRs) and meta-analyses (Mas) on QSYQ for CHD were collected by searching six databases and evaluated using the Assessment of Multiple Systematic Reviews 2 (AMSTAR 2). The grading of recommendations assessment, development, and evaluation (GRADE) system was applied to assess the quality of outcomes.

Results: Five SRs/MAs were analyzed and twenty-four outcome indicators were reported. The AMSTAR 2 revealed that 3 (12.5 %) of the outcome indicators were of moderate quality, 6 (25 %) were of low quality, and 15 (62.5 %) were of deficient quality. Five SRs/MAs (80 %) described adverse reactions, with two reporting no significant adverse reactions and two reporting minor adverse reactions (p > 0.05).

Conclusion: Combining QSYQ with conventional therapy improves CHD patients' electrocardiogram and overall health outcomes. Future high-quality clinical trials and standardized study methods are needed to further investigate the safety of QSYQ.

Keywords: Qishen Yiqi Drop Pill, Coronary heart disease, Systematic reviews, Meta-analysis, Overview